The Clorox Company (NYSE:CLX) Shares Acquired by IFM Investors Pty Ltd

IFM Investors Pty Ltd raised its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 13.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,185 shares of the company's stock after purchasing an additional 3,071 shares during the period. IFM Investors Pty Ltd's holdings in Clorox were worth $4,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Clorox by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock worth $2,518,517,000 after buying an additional 124,428 shares during the period. Geode Capital Management LLC boosted its position in shares of Clorox by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock worth $501,925,000 after purchasing an additional 69,969 shares in the last quarter. Stifel Financial Corp boosted its position in shares of Clorox by 0.4% in the 4th quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock worth $380,761,000 after purchasing an additional 9,582 shares in the last quarter. Norges Bank acquired a new stake in shares of Clorox in the 4th quarter worth $259,041,000. Finally, Northern Trust Corp raised its stake in Clorox by 18.2% in the 4th quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock worth $242,684,000 after acquiring an additional 230,173 shares during the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on CLX. Jefferies Financial Group reduced their target price on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Morgan Stanley reduced their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. UBS Group reduced their price objective on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Citigroup reduced their price objective on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research note on Monday, April 14th. Finally, Evercore ISI set a $140.00 price objective on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, Clorox currently has an average rating of "Hold" and an average target price of $149.50.

Insider Transactions at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the acquisition, the director owned 4,000 shares in the company, valued at approximately $546,280. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.57% of the company's stock.

Clorox Price Performance

Shares of NYSE:CLX traded down $0.29 during trading on Monday, reaching $124.55. 1,478,662 shares of the company's stock traded hands, compared to its average volume of 1,402,446. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37. The firm has a market cap of $15.35 billion, a PE ratio of 22.36, a P/E/G ratio of 3.04 and a beta of 0.51. The company has a 50-day simple moving average of $129.65 and a 200-day simple moving average of $143.60.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the previous year, the firm posted $1.71 earnings per share. The company's quarterly revenue was down 8.0% on a year-over-year basis. As a group, analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.